Clinical trial

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07198841

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-11-03

PhasePHASE2

Study timeline

Study start (actual)2025-11-03Date precision: day

Registry last updated2026-03-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancer (Non-Small Cell)unresolved

Interventions

IBI351 combined with cetuximab βDRUG

Sponsors & collaborators

Guangdong Association of Clinical Trialslead sponsor

Innovent Biologics (Suzhou) Co. Ltd.collaborator

Mabpharm Limitiedcollaborator

Mapped research locations

GuangzhouGuangdong, China1 BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07198841 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.